Billiontoone (NASDAQ:BLLN) Given New $125.00 Price Target at JPMorgan Chase & Co.
by Scott Moore · The Cerbat GemBilliontoone (NASDAQ:BLLN – Free Report) had its target price boosted by JPMorgan Chase & Co. from $120.00 to $125.00 in a research note issued to investors on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.
Several other equities analysts have also weighed in on BLLN. BTIG Research reduced their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday. Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Wells Fargo & Company reduced their target price on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Guggenheim decreased their price target on shares of Billiontoone from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Billiontoone in a research report on Friday, May 1st. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Billiontoone presently has a consensus rating of “Moderate Buy” and an average target price of $122.43.
Read Our Latest Stock Analysis on BLLN
Billiontoone Stock Performance
Shares of NASDAQ:BLLN traded down $1.11 on Thursday, hitting $91.79. The company’s stock had a trading volume of 836,819 shares, compared to its average volume of 348,056. The firm has a market capitalization of $4.22 billion and a P/E ratio of 437.10. The company has a quick ratio of 11.32, a current ratio of 11.69 and a debt-to-equity ratio of 0.12. Billiontoone has a 12 month low of $61.96 and a 12 month high of $138.70. The company’s 50-day moving average price is $77.96.
Billiontoone (NASDAQ:BLLN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to the consensus estimate of $95.81 million. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. Billiontoone’s revenue for the quarter was up 83.8% compared to the same quarter last year. Equities analysts expect that Billiontoone will post 0.42 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Billiontoone
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Emerald Mutual Fund Advisers Trust boosted its position in Billiontoone by 11.9% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock valued at $10,436,000 after purchasing an additional 14,072 shares during the last quarter. Emerald Advisers LLC increased its stake in shares of Billiontoone by 26.8% during the 1st quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock worth $18,911,000 after purchasing an additional 50,613 shares during the last quarter. Wasatch Advisors LP bought a new stake in Billiontoone in the first quarter worth $29,179,000. Caitong International Asset Management Co. Ltd acquired a new position in Billiontoone during the fourth quarter worth $230,000. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Billiontoone during the fourth quarter worth $8,277,000.
Billiontoone Company Profile
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.